Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation

European Journal of Internal Medicine

Volumn 54, Issue , 2018, Pages 34-39

  Pastori, Daniele ^a,b   Farcomeni, Alessio ^c   Saliola, Mirella ^a   Del Sole, Francesco ^a   Pignatelli, Pasquale ^a   Violi, Francesco ^a   Lip, Gregory Y H ^b,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

Anticoagulation; Atrial fibrillation; Cardiovascular events; Time in therapeutic range; Vitamin K antagonists

Indexed keywords

AMIODARONE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTON PUMP INHIBITOR; SARTAN DERIVATIVE; VERAPAMIL; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREND STUDY; ANTAGONISTS AND INHIBITORS; BLEEDING; CEREBROVASCULAR ACCIDENT; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; ITALY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K;

EID: 85045206087     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2018.04.007     Document Type: Article

References (32)

1. Violi, F., Soliman, E.Z., Pignatelli, P., Pastori, D., Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc, 5, 2016.
2. Sjogren, V., Grzymala-Lubanski, B., Renlund, H., Friberg, L., Lip, G.Y., Svensson, P.J. et al., Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 113 (2015), 1370–1377.
3. Connolly, S.J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M.G. et al., Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118 (2008), 2029–2037.
4. Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P. et al., Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 1 (2008), 84–91.
5. Xian, Y., O'Brien, E.C., Liang, L., Xu, H., Schwamm, L.H., Fonarow, G.C. et al., Association of Preceding Antithrombotic Treatment with Acute Ischemic Stroke Severity and in-Hospital Outcomes among Patients with Atrial Fibrillation. JAMA 317 (2017), 1057–1067.
6. Gallego, P., Roldan, V., Marin, F., Romera, M., Valdes, M., Vicente, V. et al., Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 110 (2013), 1189–1198.
7. Bertomeu-Gonzalez, V., Anguita, M., Moreno-Arribas, J., Cequier, A., Muniz, J., Castillo-Castillo, J. et al., Quality of anticoagulation with vitamin K antagonists. Clin Cardiol 38 (2015), 357–364.
8. Chan, P.H., Li, W.H., Hai, J.J., Chan, E.W., Wong, I.C., Tse, H.F. et al., Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Can J Cardiol 32:1247 (2016), e23–e28.
9. Pastori, D., Pignatelli, P., Saliola, M., Carnevale, R., Vicario, T., Del Ben, M. et al., Inadequate anticoagulation by vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation. Int J Cardiol 201 (2015), 513–516.
10. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B. et al., ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J, 2016, 2016.
11. Haas, S., Ten Cate, H., Accetta, G., Angchaisuksiri, P., Bassand, J.P., Camm, A.J. et al., Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One, 11, 2016, e0164076.
12. Apostolakis, S., Sullivan, R.M., Olshansky, B., Lip, G.Y., Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin: the SAMe-TT2R2 (Sex female, Age less than 60, Medical history, Treatment strategy [rhythm control], Tobacco use [doubled], Race [doubled] score). Chest 144:5 (Nov 2013), 1555–1563, 10.1378/chest.13-0054.
13. Martinez, C., Katholing, A., Wallenhorst, C., Freedman, S.B., Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 115 (2016), 31–39.
14. Gallagher, A.M., Rietbrock, S., Plumb, J., van Staa, T.P., Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost 6 (2008), 1500–1506.
15. Rivera-Caravaca, J.M., Roldan, V., Esteve-Pastor, M.A., Valdes, M., Vicente, V., Lip, G.Y.H. et al., Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost 117 (2017), 1448–1454.
16. Raparelli, V., Proietti, M., Cangemi, R., Lip, G.Y., Lane, D.A., Basili, S., Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 117 (2017), 209–218.
17. Pastori, D., Pignatelli, P., Angelico, F., Farcomeni, A., Del Ben, M., Vicario, T. et al., Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest 147 (2015), 1644–1650.
18. Rosendaal, F.R., Cannegieter, S.C., van der Meer, F.J., Briet, E., A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69 (1993), 236–239.
19. Rose, A.J., Hylek, E.M., Ozonoff, A., Ash, A.S., Reisman, J.I., Berlowitz, D.R., Patient characteristics associated with oral anticoagulation control: results of the veterans AffaiRs study to improve anticoagulation (VARIA). J Thromb Haemost 8 (2010), 2182–2191.
20. Proietti, M., Lane, D.A., Lip, G.Y., Chronic kidney disease, time in therapeutic range and adverse clinical outcomes in anticoagulated patients with non-valvular atrial fibrillation: observations from the SPORTIF trials. EBioMedicine 8 (2016), 309–316.
21. Anguita Sanchez, M., Bertomeu Martinez, V., Cequier Fillat, A., Cs, researchers, Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Esp Cardiol (Engl Ed) 68 (2015), 761–768.
22. Odashiro, K., Yokoyama, T., Fukata, M., Arita, T., Maruyama, T., Akashi, K., Anticoagulation stability depends on CHADS2 score and Hepatorenal function in warfarin-treated patients, including those with atrial fibrillation. J Atheroscler Thromb 24 (2017), 68–76.
23. Okumura, K., Komatsu, T., Yamashita, T., Okuyama, Y., Harada, M., Konta, Y. et al., Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - a multicenter study of its status and infuential factors. Circ J 75 (2011), 2087–2094.
24. Park, Y.K., Lee, M.J., Kim, J.H., Lee, J.S., Park, R.W., Kim, G.M. et al., Genetic and non-genetic factors affecting the quality of anticoagulation control and vascular events in atrial fibrillation. J Stroke Cerebrovasc Dis 26 (2017), 1383–1390.
25. Pastori, D., Pignatelli, P., Perticone, F., Sciacqua, A., Carnevale, R., Farcomeni, A. et al., Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. Int J Cardiol 223 (2016), 619–624.
26. Chen, P.C., Lip, G.Y., Yeh, G., Lin, H.J., Chien, K.L., Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. PLoS One, 10, 2015, e0125257.
27. Hashikata, T., Yamaoka-Tojo, M., Kakizaki, R., Nemoto, T., Fujiyoshi, K., Namba, S. et al., Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. Heart Vessels 32 (2017), 47–54.
28. Marie, I., Leprince, P., Menard, J.F., Tharasse, C., Levesque, H., Risk factors of vitamin K antagonist overcoagulation. QJM 105 (2012), 53–62.
29. 1.
30. Henriksen, D.P., Stage, T.B., Hansen, M.R., Rasmussen, L., Damkier, P., Pottegard, A., The potential drug-drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf 24 (2015), 1337–1340.
31. Dahal, K., Sharma, S.P., Kaur, J., Anderson, B.J., Singh, G., Efficacy and safety of proton pump inhibitors in the long-term aspirin users: a meta-analysis of randomized controlled trials. Am J Ther, 24, 2017, e559-e69.
32. Velagapudi, P., Turagam, M.K., Leal, M.A., Kocheril, A.G., Atrial fibrillation and acid reflux disease. Clin Cardiol 35 (2012), 180–186.